Hyloris Announces New Exclusive Licensing Agreement for Maxigesic® IV in China

Exclusive Licensing Agreement AFT with Chengdu Tongde Pharmaceuticals Co., Ltd.

Liège, Belgium – July 14, 2026 – 23:30 PM CET – Regulated information – Inside information – Hyloris Pharmaceuticals SA ("Hyloris") (Euronext Brussels: HYL), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announced that its partner AFT Pharmaceuticals ("AFT") has entered into an exclusive licensing agreement with Chengdu Tongde Pharmaceuticals Co., Ltd. ("Tongde") for the development, manufacture and commercialization of Maxigesic® IV in Mainland China.

Under the agreement, Tongde will fund and carry out the CMC activities, clinical studies and other work required to obtain regulatory approval for Maxigesic® IV in China. Following approval, Tongde will manufacture and commercialize the product and pay royalties on net sales, with Hyloris entitled to a significant minority share under its existing agreement with AFT.

In anticipation of this exclusive licensing agreement, the previous licensing agreement for Maxigesic® IV in China has been terminated.

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: "*China represents an important potential market for Maxigesic® IV. We are pleased that AFT has entered into this agreement with Tongde, establishing a pathway for the commercialization of Maxigesic® IV in China*."

About Maxigesic® IV

Maxigesic® IV is an intravenous formulation combining paracetamol 1,000 mg and ibuprofen 300 mg in a single solution for infusion. The product is intended for the treatment of mild to moderate pain where an intravenous route of administration is clinically appropriate. Maxigesic® IV offers a non-opioid analgesic option and is protected by a portfolio of patents in several territories. Maxigesic® IV was developed by Hyloris and AFT Pharmaceuticals and is commercialized in multiple markets through a network of partners.

About Chengdu Tongde Pharmaceuticals Co., Ltd.

Chengdu Tongde Pharmaceuticals Co., Ltd. is a pharmaceutical company organized under the laws of the People's Republic of China, with its principal place of business in Wenjiang District, Chengdu, Sichuan Province. Under its agreement with AFT, Tongde is the exclusive licensee responsible for the development, manufacture and commercialization of Maxigesic® IV in Mainland China.

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio of 28 products, including 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid injectable pain treatment. In

addition to its core strategic focus, the Company has two high-barrier generic products approved in the U.S. and one additional high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide***. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).

For more information, visit www.hyloris.com and follow us on LinkedIn.

Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO
legal representative of Impact WITH Empathy BV
Ann.dejaeger@hyloris.com
+32 (0)475 20 13 44 - +32 (0)4 346 02 07

Stijn Van Rompay, CEO
legal representative of SVR Management BV
stijn.vanrompay@hyloris.com
+32 (0)4 346 02 07

Christophe Maréchal, CFO
legal representative of CMM&C srl
Christophe.Marechal@hyloris.com
+32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
This press release contains information about a product under development and is not intended as a promotional statement. The product mentioned is subject to regulatory approval and is not currently available for sale. Please consult licensed medical professionals for healthcare decisions.